ADVM · As filed with the SEC

Adverum Biotechnologies cash flow statement, by quarter

The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Condensed Consolidated Statements of Cash Flows · USD thousands

USD thousands	Q3 2025^† 3 months ended Sep 30, 2025	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024	Q3 2024^† 3 months ended Sep 30, 2024	Q2 2024^† 3 months ended Jun 30, 2024	Q4 2023^† 3 months ended Dec 31, 2023
Cash flows from operating activities:
Net loss	(47,652)^†	(49,191)^†	(47,019)	(40,931)^†	(12,752)^†	(16,116)^†	(23,714)^†
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	465^†	535^†	683	810^†	890^†	956^†	1,009^†
Stock-based compensation expense	2,349^†	2,423^†	2,778	3,275^†	2,964^†	3,945^†	4,148^†
Net accretion of discount on marketable securities	(16)^†	(92)^†	(436)	(614)^†	(518)^†	(442)^†	(100)^†
Non-cash lease expense	83^†	55^†	27	6,152^†	543^†	484^†	561^†
Non-cash sublease loss	0^†	0^†	982	—	3,712^†	3,719^†	—
Loss on disposal of property and equipment	—	—	—	0^†	—	—	(35)^†
Other	1^†	13^†	(1)	(46)^†	16^†	10^†	258^†
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,135^†	2,345^†	(777)	2,230^†	(2,248)^†	176^†	1,221^†
Deposit and other long-term assets and deferred rent receivable	—	—	—	—	(284)^†	—	39^†
Deposit and other long-term assets	(551)^†	18^†	(143)	(6)^†	(131)^†	34^†	—
Accounts payable	7,739^†	2,885^†	218	(449)^†	298^†	236^†	(307)^†
Accrued expenses and other liabilities	7,190^†	3,199^†	426	686^†	4,974^†	752^†	(3,754)^†
Lease liability	—	—	—	—	(626)^†	—	—
Lease liability	1,134^†	(957)^†	491	(4,879)^†	953^†	785^†	—
Net cash used in operating activities	(28,115)^†	(38,767)^†	(42,771)	(28,249)^†	(21,124)^†	(19,844)^†	(21,328)^†
Cash flows from investing activities:
Purchases of marketable securities	0^†	(1,976)^†	0	(19,128)^†	(33,325)^†	(22,511)^†	(16,486)^†
Maturities of marketable securities	2,000^†	34,000^†	31,500	15,000^†	20,200^†	20,200^†	6,800^†
Purchases of property and equipment	(142)^†	(120)^†	(220)	(61)^†	(221)^†	(16)^†	(192)^†
Net cash provided by (used in) investing activities	1,858^†	31,904^†	31,280	(4,189)^†	(13,346)^†	(2,327)^†	(9,878)^†
Cash flows from financing activities:
Payment of deferred offering costs	—	—	—	0^†	0^†	—	(76)^†
Proceeds from issuance of common stock and pre-funded warrants in private placements, net of issuance costs	9,899^†	0^†	0	—	0^†	(380)^†	—
Proceeds from issuance of common stock pursuant to option exercises	0^†	0^†	0	7^†	0^†	0^†	0^†
Proceeds from employee stock purchase plan	0^†	—	—	232^†	0^†	—	242^†
Net cash provided by financing activities	9,899^†	120^†	0	239^†	0^†	(116)^†	166^†
Net (decrease) increase in cash and cash equivalents and restricted cash	(16,358)^†	(6,743)^†	(11,491)	(32,199)^†	(34,470)^†	(22,287)^†	(31,040)^†
Cash and cash equivalents and restricted cash at beginning of period	44,394	51,137	62,628	94,827	129,297	151,584	108,016
Cash and cash equivalents and restricted cash at end of period	28,036	44,394	51,137	62,628	94,827	129,297	76,976
Supplemental schedule of noncash investing and financing information
Issuance costs included in accounts payable	—	—	0	—	—	—	—
Remeasurement of operating lease right-of-use assets	—	—	—	—	0^†	—	—
Issuance costs included in accrued expenses	—	—	—	—	0^†	—	—
Property and equipment in accounts payable, accrued expenses and other current liabilities	(33)^†	—	—	141^†	(161)^†	—	91^†

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.